A Phase 1 Dose Escalation Trial of SKI-G-801 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
The goal of this clinical research study is to find the highest tolerable dose of SKI-G-801 that can be given to patients with acute myeloid leukemia (AML). Researchers also want to learn about the safety and effectiveness of the study drug. This is the first study using SKI-G-801 in humans.
Treatment Location: N/A
IRB Review and Approval Date: 09/26/2018
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: